Mentions
Extended reach
Total likes
Video views
AI synopsis
Many discussions highlight the promising results, with references to high remission rates (e.g., 90% in pediatric ALL trials), using words like 'published results' and 'potential connection' to convey excitement and curiosity. The tone ranges from clinical acknowledgment to speculative queries, underscoring both confidence in findings and interest in broader implications.
Most posts acknowledge the effectiveness of the therapy, such as high remission rates and positive trial results, indicating general consensus on its promising nature.
Discussions show strong interest, especially with mentions of trial outcomes, historical context, and potential connections to zoonotic pathogens, sparking curiosity.
Some posts delve into specific studies and question potential broader implications, reflecting moderate engagement with technical details.
The emphasis on trial success, remission rates, and future connections suggests an awareness of the treatment's significant impact on cancer therapy.
On reporting fewer than 5 #genetherapy patients: @ScienceTM 2011 reported 3 CAR T pts, cited by 2,516 https://t.co/lFgvmTAfRE @NEJM 2011 case report on one of the above pts, cited by 4,081 https://t.co/nrB8GLdnAT
Wondering if there is a Connection to these “Zoonotic Pathogens” & “Chimeric Antigen Receptor T Cells”? https://t.co/GW0e5cNvIO https://t.co/PSNc6ZTOeX Thoughts? @aime3verde https://t.co/jfvAwVWK8s https://t.co/Z0HpdxdbEd
Q342 answer: Acute lymphoblastic leukemia https://t.co/iMu9IPrcpl https://t.co/2ghV9an9fl https://t.co/6SFnJpj3tq https://t.co/VNpNA7RdgI https://t.co/WpYRzF2fE0
https://t.co/AnWS3VcfHh
RT @BLLPHD: On reporting fewer than 5 #genetherapy patients: @ScienceTM 2011 reported 3 CAR T pts, cited by 2,516 https://t.co/lFgvmTAfRE…
RT @cells_nnm: CHOP/ Penn team published results of Ph1 trial for CART-19 cells in pediatric ALL - CR 90% http://t.co/hdSLUQ3XgV
Chimeric antigen receptor T cell therapy targeting CD19 demonstrates high effectiveness in inducing remission in relapsed or refractory acute lymphoblastic leukemia, with most patients achieving complete remission and…
Chimeric antigen receptor T cell therapy targeting CD19 shows high effectiveness in inducing remission in leukemia patients, including those who failed previous treatments. Most patients achieved complete remission…
RT @StuckInStock: $NVS Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia — NEJM http://t.co/4bfTMfgQIS http://t.co/eKP…
RT @BLLPHD: On reporting fewer than 5 #genetherapy patients: @ScienceTM 2011 reported 3 CAR T pts, cited by 2,516 https://t.co/lFgvmTAfRE…
RT @BLLPHD: On reporting fewer than 5 #genetherapy patients: @ScienceTM 2011 reported 3 CAR T pts, cited by 2,516 https://t.co/lFgvmTAfRE…
On reporting fewer than 5 #genetherapy patients: @ScienceTM 2011 reported 3 CAR T pts, cited by 2,516 https://t.co/lFgvmTAfRE @NEJM 2011 case report on one of the above pts, cited by 4,081 https://t.co/nrB8GLdnAT
Wondering if there is a Connection to these “Zoonotic Pathogens” & “Chimeric Antigen Receptor T Cells”? https://t.co/GW0e5cNvIO https://t.co/PSNc6ZTOeX Thoughts? @aime3verde https://t.co/jfvAwVWK8s https://t.co/Z0HpdxdbEd
Q342 answer: Acute lymphoblastic leukemia https://t.co/iMu9IPrcpl https://t.co/2ghV9an9fl https://t.co/6SFnJpj3tq https://t.co/VNpNA7RdgI https://t.co/WpYRzF2fE0
https://t.co/AnWS3VcfHh
RT @cells_nnm: CHOP/ Penn team published results of Ph1 trial for CART-19 cells in pediatric ALL - CR 90% http://t.co/hdSLUQ3XgV
10.1056/NEJMoa1407222. Crossref · PubMed · Web of Science · Google Scholar. 35. D. M. Barrett, D. T. Teachey, S. A. Grupp, Toxicity management for patients ...
org/doi/full/10.1056/nejmoa1407222#t=article https://www.nature.com/articles/nrc.2016.97 (Hình ảnh: từ Internet). Nguyen Nguyen and 26 others.
org/doi/full/10.1056/nejmoa1407222#t=article https://www.nature.com/articles/nrc.2016.97 (Hình ảnh: từ Internet) · Nguyen Nguyen and 26 others.
org/doi/full/10.1056/nejmoa1407222#t=article https://www.nature.com/articles/nrc.2016.97 (Hình ảnh: từ Internet). Nguyen Nguyen and 26 others.
doi:10.1056/NEJMoa1407222; Porter DL, Hwang WT, Frey NV, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in ...
... 10.1056/NEJMoa1407222 PMID: 25317870 PMCID: 4267531. 13. June CH and Sadelain M (2018) Chimeric antigen receptor therapy N Engl J Med 379(1) ...
doi:10.1056/NEJMoa1407222; Grupp SA, Maude SL, Shaw P, et al. T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 ...
10.1056/NEJMoa1407222. GO TO REFERENCE. Crossref · PubMed · Web of Science · Google Scholar. 35. D. M. Barrett, D. T. Teachey, S. A. Grupp, ...
2014;doi:10.1056/NEJMoa1407222. Teachy DT, et al. Cancer Discov. 2016;doi:10.1158/2159-8290.CD-16-0040. Stephan A. Grupp, MD, PhD. Children's ...
doi: 10.1056/NEJMoa1407222. Almasbak H, Aarvak T, Vemuri MC. CAR T cell therapy: a game changer in cancer treatment. J Immunol Res. 2016 ...
doi: 10.1056/NEJMoa1103782. pmid:21639808. 4. Hodi FS, O'Day SJ ... doi: 10.1056/NEJMoa1407222. pmid:25317870. View Figures (1) · View ...
2014;doi:10.1056/NEJMoa1407222. Neelapu SS, et al. Abstract 7559. Presented at: ASCO Annual Meeting; June 3-7, 2016; Chicago. Porter DL, et ...
Here are Phase III results as a follow-up for the "HIV to kill cancer" segment. http://www.nejm.org/doi/full/10.1056/NEJMoa1407222. Community ...
... 10.1056/NEJMoa1407222. Journal information: New England Journal of Medicine. Provided by Cancer Research UK. + Explore further. Immune therapy ...
NEJM DOI: 10.1056/NEJMoa1407222. Lees ook: Nieuw type leukemie ontdekt · Bescherming tegen leukemie · Effecten chemotherapie. © iStock.
2014;doi:10.1056/NEJMoa1407222. Healio AI. Ask a clinical question and tap into Healio AI's knowledge base. PubMed, enrolling/recruiting ...
Nio av tio patienter med långt framskriden akut lymfatisk leukemi, ALL, blev sjukdomsfria efter behandling med genetiskt modifierade ...
BD
P
BS
IS
CM
AB
お戦
II